Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 5, 2011 Brian Orelli	Drug Approved, But No Fireworks Yet The second FDA approval for Bayer and Johnson & Johnson's Xarelto is more important.
The Motley Fool April 6, 2011 Brian Orelli	$1 Billion in Drug Sales Bleeds Out Don't feel too bad for Bayer and J&J though.
The Motley Fool March 18, 2009 Brian Orelli	Johnson & Johnson and Shakespeare The stage is set for a dramatic decision.
The Motley Fool September 7, 2011 Brian Orelli	J&J and Bayer Head in Front of the Firing Squad An expanded indication for Xarelto seems unlikely.
The Motley Fool September 11, 2007 Brian Lawler	Where Momenta Stands Momenta Pharmaceuticals updates investors as to the status of drugs in its pipeline. Until the FDA makes up its mind on its lead drug, an anticoagulant, it's anyone's guess as to what the value of the pipeline is. Investors should take note.
The Motley Fool May 15, 2008 Brian Orelli	Wanted: FDA Approval -- Pronto Teva and Amphastar have the courts on their side, but the FDA still stands in the way of a generic-drug launch.
The Motley Fool November 30, 2011 Brian Orelli	Drugmakers Bleeding Out That's not what blood thinners are supposed to do.
The Motley Fool July 28, 2010 Brian Orelli	Fighting Hard to Keep a Blockbuster Sanofi is suing the FDA to take back approval of a competing generic drug. Did you expect something different?
The Motley Fool November 2, 2010 Travis Hoium	Momenta Pharmaceuticals Shares Plunged: What You Need to Know Momenta Pharmaceuticals shares fell 10% in trading early Tuesday after Teva Pharmaceutical Industries said it expects FDA approval this year on a drug to compete with Momenta's enoxaparin.
The Motley Fool November 6, 2006 Brian Lawler	The Impending Verdict on Momenta The drug developer isn't willing to wait for potential legislation on generic drugs. Investors, take note.
The Motley Fool February 15, 2007 Brian Lawler	A Momenta's Pause The pharmaceutical elaborates on plans for its generic version of blockbuster Lovenox. With so much going on, the rest of 2007 is sure to be a wild ride for Momenta investors.
The Motley Fool November 22, 2010 Brian Orelli	Pfizer's Mixed Bag Pfizer had a mixed bag of clinical trial results at the end of last week. And probably the company would have rather seen the results flip-flopped.
The Motley Fool October 31, 2007 Brian Lawler	Sanofi: Stable, for Now The drugmaker's healthy Q3 results shine amid slumping competitors. Investors, take note.
The Motley Fool June 11, 2010 Brian Orelli	Pfizer and Bristol Coagulate Against Clots Let's see how apixaban does against warfarin before we break out the "blockbuster" stamp.
The Motley Fool May 9, 2007 Brian Lawler	Where Is Momenta's Momentum? Momenta awaits an FDA regulatory decision and announces quarterly financial results. Investors, take note.
The Motley Fool February 14, 2008 Brian Lawler	Sanofi Stagnates French drugmaker Sanofi-Aventis posts fourth-quarter earnings in which its top drugs get some protection, but free cash flow drops.
The Motley Fool November 26, 2010 Brian Orelli	Black Friday Biotech Bargains Drugmakers on sale.
The Motley Fool May 29, 2009 Brian Orelli	Delayed, Reason Unknown As long as Bayer and Johnson & Johnson can answer the FDA's questions relatively quickly, it shouldn't affect the companies too much.
The Motley Fool October 30, 2009 Brian Orelli	Shrugging Off the Side Effects Sanofi-aventis is looking good, but still faces the patent protection loss of Lovenox.
The Motley Fool October 31, 2011 Brian Orelli	5 One-Drug Wonders Going for No. 2 Here are five drugmakers hoping not to become one-hit wonders: Vertex... Onyx... Momenta... Elan... Dendreon...
The Motley Fool December 30, 2010 Brian Orelli	2011 Drugmaker M&A Targets What Big Pharma M&A deals will 2011 hold? Most likely, more small deals, and perhaps Sanofi will finally offer a reasonable price for Genzyme. Let's take a look at some of the companies that might be walking down the aisle next year.
The Motley Fool March 23, 2010 Brian Orelli	No Patent! No Generics? Take Advantage of the Situation Enjoy it while it lasts, pharma.
The Motley Fool June 23, 2010 Brian Orelli	Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise.
The Motley Fool May 2, 2011 Brian Orelli	Prostate Cancer Drug Roars Ahead Johnson & Johnson's buy of Cougar paid off, but look in the rear view mirror.
The Motley Fool May 29, 2009 Brian Orelli	The Clouds Are Parting The Food and Drug Administration has scheduled an advisory committee meeting for Aug. 4 to get input on whether the agency should approve generic versions of ViroPharma's antibiotic, Vancocin.
The Motley Fool February 11, 2010 Brian Orelli	A Turnaround Year, But Not in a Good Way 2009 was a solid year for sanofi-aventis thanks to a boost from sales of swine flu vaccine and some help from the exchange rate. But 2010? Not so solid.
The Motley Fool January 19, 2007 Karl Thiel	The Best Drug Stock for 2007: Momenta Investors, swing for the fences with this drug company.
The Motley Fool January 28, 2011 Brian Orelli	Looking Ahead at Bristol-Myers Product approvals now will help with the upcoming patent cliff.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool September 8, 2011 Arlene Weintraub	Bristol-Pfizer Team on Alert as FDA Reviews Stroke-Prevention Drug From Rivals J&J and Bayer Who will come out ahead?
The Motley Fool October 26, 2010 Brian Orelli	Where's the Growth in Big Pharma? The theme for the pharmaceutical industry's 2010 third-quarter earnings reports has been officially set: If you can't get it done through sales, just cut costs.
The Motley Fool September 17, 2009 Brian Orelli	Sleepless in Sanofi It's nothing but sleepless nights for sanofi-aventis, and there's no drug to cure it.
The Motley Fool March 4, 2010 Brian Orelli	Best in Class ... For Now Sanofi's new prostate cancer drug is better than nothing.
The Motley Fool September 15, 2008 Brian Orelli	Teva and FDA's Never-Ending Court Battle The Food and Drug Administration has won the latest installment of its grudge match with Teva Pharmaceuticals over the 180-day exclusivity period for generic versions of Johnson & Johnson's Risperdal.
The Motley Fool August 24, 2009 Brian Orelli	J&J Would Rather Not Say Drug delayed, reason unknown. Should shareholders be worried? It's hard to tell.
The Motley Fool July 21, 2011 Brian Orelli	Keep an Eye on Biotech Partners' Earnings Novartis' earnings are important for small biotechs Momenta and Vanda.
The Motley Fool November 7, 2007 Brian Orelli	Momenta Stopped Momenta and Novartis receive a not-approvable letter for their new drug application on their generic version of Lovenox, due to worries that it might cause an immune reaction. Investors, take note.
The Motley Fool July 23, 2010 Luke Timmerman	Momenta Gets FDA Green Light for Generic Anti-Clotting Drug The FDA says "yes" to Momenta Pharmaceuticals.
The Motley Fool September 27, 2010 Brian Orelli	This Recall Is Different -- In a Good Way Johnson & Johnson strikes again, but it's not so bad this time.
The Motley Fool February 22, 2010 Brian Orelli	So Long, See You in Arbitration After another rejection, Johnson & Johnson and Basilea call it quits.
The Motley Fool May 13, 2008 Brian Lawler	Sanofi Can't Shake the Generics A new threat to the pharmaceutical's top drug may have arrived.
The Motley Fool October 26, 2011 Brian Orelli	Momenta Stopped. Again. Oh, no - an authorized generic gets launched.
The Motley Fool July 1, 2008 Brian Orelli	As the FDA Generics Office Turns The FDA reluctantly gives Teva a 180-day exclusive period to sell generic Risperdal.
The Motley Fool December 11, 2006 Brian Lawler	Weighing In on Sanofi's Acomplia With the future of Sanofi's two top drugs in the hands of the courts, plus any Acomplia approval subject to the whims of the FDA, investors should wait on the sidelines until these judicial and regulatory decisions have been made.
The Motley Fool August 29, 2008 Brian Orelli	A Lawsuit Loss to Remember Barr Pharmaceuticals and Mylan get the patent overturned on Johnson & Johnson's Alzheimer's drug.
The Motley Fool March 19, 2009 Brian Orelli	One Down, One to Go Sanofi-aventis slides past an FDA panel and hopes for more good news today
The Motley Fool October 19, 2011 Brian Orelli	Not the Best Quarter, but... There's little reason to worry about Johnson & Johnson.
The Motley Fool February 12, 2009 Brian Orelli	Patent Cliff? Bring It On Sanofi-aventis isn't interested in doing a large deal.
The Motley Fool July 27, 2010 Brian Orelli	Branded? Generic? They're Both Doing Great! Teva Pharmaceuticals registers strong growth on both fronts.
The Motley Fool May 7, 2007 Brian Lawler	Sanofi Rolls the Lawsuit Dice Investors, don't be fooled by rosy results; litigation risk still looms for the French drugmaker.